6BG Stock Overview
A, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Lytix Biopharma AS Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NOK 0.68 |
52 Week High | NOK 1.04 |
52 Week Low | NOK 0.41 |
Beta | -0.67 |
11 Month Change | 16.33% |
3 Month Change | -11.86% |
1 Year Change | 39.59% |
33 Year Change | -49.11% |
5 Year Change | n/a |
Change since IPO | -56.60% |
Recent News & Updates
Recent updates
Shareholder Returns
6BG | DE Biotechs | DE Market | |
---|---|---|---|
7D | 32.6% | 1.9% | 1.5% |
1Y | 39.6% | -15.1% | 8.8% |
Return vs Industry: 6BG exceeded the German Biotechs industry which returned -15.1% over the past year.
Return vs Market: 6BG exceeded the German Market which returned 8.8% over the past year.
Price Volatility
6BG volatility | |
---|---|
6BG Average Weekly Movement | 11.3% |
Biotechs Industry Average Movement | 6.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 11.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6BG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6BG's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | n/a | Oystein Rekdal | www.lytixbiopharma.com |
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.
Lytix Biopharma AS Fundamentals Summary
6BG fundamental statistics | |
---|---|
Market cap | €31.99m |
Earnings (TTM) | -€6.96m |
Revenue (TTM) | €924.84k |
34.6x
P/S Ratio-4.6x
P/E RatioIs 6BG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6BG income statement (TTM) | |
---|---|
Revenue | NOK 10.76m |
Cost of Revenue | NOK 0 |
Gross Profit | NOK 10.76m |
Other Expenses | NOK 91.68m |
Earnings | -NOK 80.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.63 |
Gross Margin | 100.00% |
Net Profit Margin | -752.26% |
Debt/Equity Ratio | 0% |
How did 6BG perform over the long term?
See historical performance and comparison